[A case of effective neoadjuvant chemotherapy (MVEC) against right ureteral cancer involving bladder (cT4N1M0)]

Hinyokika Kiyo. 2014 Apr;60(4):179-82.
[Article in Japanese]

Abstract

Poorly differentiated ureteral cancer has a poor prognosis, and tumor recurrence is frequent even after nephroureterectomy. We performed neoadjuvant chemotherapy to prevent postoperative recurrence. A 74-year-old man was diagnosed with ureteral cancer (3 cm) by magnetic resonance imaging (MRI). The clinical stage was T4N1M0. Histological examination by transurethral biopsy revealed an urothelial carcinoma, G3, pT1. After a month, the tumor size increased from 3.0 cm to 4.0 cm. With two cycles of neoadjuvant chemotherapy consisting of methotrexate, vinblastine, epirubicin and cisplatin (MVEC) partial remission (regression rate : 87%) was achieved, Following MVEC, right retroperitoneoscopy-assisted nephroureterectomy, total cystectomy, and ileal conduit were performed. Pathological stage was pT0. After two years, postoperative recurrence has not appeared.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Antibiotics, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Cisplatin / administration & dosage
  • Epirubicin / administration & dosage
  • Humans
  • Male
  • Methotrexate / administration & dosage
  • Neoadjuvant Therapy*
  • Treatment Outcome
  • Ureteral Neoplasms / pathology
  • Ureteral Neoplasms / therapy*
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy*
  • Vinblastine / administration & dosage

Substances

  • Antibiotics, Antineoplastic
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Epirubicin
  • Vinblastine
  • Cisplatin
  • Methotrexate